Image pharmaphorum Editor News Indivior's once-monthly schizophrenia injection gets US gree... Regulators authorities in the US have approved Indivior’s long-acting injectable treatment for adults with schizophrenia. News GSK's Nucala unlikely to get COPD use after panel vote FDA due to make decision in September News PureTech to research Alzheimer's drugs based on 'brain drain... US biotech PureTech Health is to develop therapies that are based on a new theory that neurological diseases such as Alzheimer’s are linked to drainage issues in the brain. News Philanthropists donate $30m towards finding Alzheimer’s cure A coalition of philanthropists has announced they are donating more than $30 million in a drive to combat Alzheimer’s disease. Load more results
News Indivior's once-monthly schizophrenia injection gets US gree... Regulators authorities in the US have approved Indivior’s long-acting injectable treatment for adults with schizophrenia.
News PureTech to research Alzheimer's drugs based on 'brain drain... US biotech PureTech Health is to develop therapies that are based on a new theory that neurological diseases such as Alzheimer’s are linked to drainage issues in the brain.
News Philanthropists donate $30m towards finding Alzheimer’s cure A coalition of philanthropists has announced they are donating more than $30 million in a drive to combat Alzheimer’s disease.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
